vTv announces Phase III plans for type 1 diabetes drug cadisegliatin
vTv plans to initiate a Phase III study for cadisegliatin with an FDA-recommended primary endpoint by the end of 2023.
vTv plans to initiate a Phase III study for cadisegliatin with an FDA-recommended primary endpoint by the end of 2023.
What's Your Reaction?
